This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

NICE guidance - Adalimumab for the treatment of psoriasis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Summary features of the guidance (1):

  • NICE state that:
    • adalimumab is recommended as a possible treatment for adults with plaque psoriasis only if:
      • their condition is severe and
      • their condition has not improved with other treatments such as ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or they have had side effects with these in the past or there is a medical reason why they should not be given these treatments.
    • adalimumab treatment should be continued beyond 16 weeks only if the psoriasis has clearly improved within this time.
    • severity of a person's psoriasis before and during treatment should be assessed by considering the redness, thickness and scaliness of the plaques, the area of the body involved, and how the condition affects the person's quality of life.

For further details then consult the full guideline (1).


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page